Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for Climb Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($2.73) per share for the year. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share.
Separately, Leerink Partners initiated coverage on shares of Climb Bio in a research note on Monday, December 2nd. They issued an "outperform" rating and a $10.00 price objective on the stock.
Get Our Latest Report on CLYM
Climb Bio Stock Performance
Shares of NASDAQ CLYM traded down $0.04 during midday trading on Friday, hitting $1.55. The stock had a trading volume of 142,434 shares, compared to its average volume of 446,110. Climb Bio has a fifty-two week low of $1.54 and a fifty-two week high of $11.55. The stock has a market cap of $103.86 million, a price-to-earnings ratio of -0.73 and a beta of -0.24. The stock has a 50-day simple moving average of $2.14.
Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter.
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Recommended Stories
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
